Is the duration of adjuvant trastuzumab debate still clinically relevant?

Lancet. 2019 Jun 29;393(10191):2565-2567. doi: 10.1016/S0140-6736(19)30946-8. Epub 2019 Jun 6.

Author

Sara A Hurvitz¹

Affiliation

¹ David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA. Electronic address: shurvitz@mednet.ucla.edu.

PMID: 31178153
DOI: 10.1016/S0140-6736(19)30946-8

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms*
Disease-Free Survival
Humans
Receptor, ErbB-2
Trastuzumab

Substances

Receptor, ErbB-2
Trastuzumab